Overview

Drug Use Investigation of Kaletra

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
0
Participant gender:
All
Summary
This non-interventional, post-marketing observational study was conducted to obtain data, such as safety and effectiveness, from the use of lopinavir/ritonavir (Kaletra) in clinical practice and investigate the necessity to conduct a follow-up post-marketing clinical study in Japan.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Abbott
Treatments:
Lopinavir
Ritonavir
Criteria
Inclusion Criteria:

- All patients prescribed Kaletra for the treatment of HIV are eligible for this survey.

Exclusion Criteria:

- Contraindications according to the Package Insert:

- Patients with a history of hypersensitivity to any ingredient of Kaletra

- Patients who are receiving pimozide, cisapride, ergotamine tartrate,
dihydroergotamine mesylate, ergometrine maleate, methylergometrine maleate,
midazolam, triazolam, vardenafil hydrochloride hydrate, boriconazol